|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
ES2798263T3
(es)
|
2005-12-08 |
2020-12-10 |
Insmed Inc |
Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
EP2679224A1
(en)
|
2007-08-01 |
2014-01-01 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Nitro oleic acid modulation of type II diabetes
|
|
US9006191B2
(en)
|
2007-12-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering RNA
|
|
EP2279254B1
(en)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
DK2280928T3
(en)
|
2008-05-01 |
2018-11-05 |
Complexa Inc |
Vinyl-substituted fatty acids
|
|
CN102099024B
(zh)
|
2008-06-19 |
2015-11-25 |
犹他大学研究基金会 |
硝化脂质在毒性医疗疗法的副作用的治疗上的用途
|
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
AU2009303345B2
(en)
*
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
EP2937418B1
(en)
*
|
2008-10-20 |
2017-10-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
AU2015249072C1
(en)
*
|
2008-10-20 |
2022-10-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
WO2010053572A2
(en)
|
2008-11-07 |
2010-05-14 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
EP3699172A3
(en)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
WO2010054384A1
(en)
|
2008-11-10 |
2010-05-14 |
Alnylam Pharmaceuticals, Inc. |
Lipids and compositions for the delivery of therapeutics
|
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
|
EP2391343B1
(en)
*
|
2009-01-29 |
2017-03-01 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
|
CA2754043A1
(en)
*
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
CA2760706C
(en)
*
|
2009-05-05 |
2019-08-06 |
Alnylam Pharmaceuticals, Inc. |
Methods of delivering oligonucleotides to immune cells
|
|
KR20220038506A
(ko)
|
2009-06-10 |
2022-03-28 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
NZ597504A
(en)
*
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
EP2449106B1
(en)
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
CA2769624C
(en)
|
2009-07-31 |
2018-09-11 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Electrophilic fatty acid derivatives as anti-inflammatory agents
|
|
US9181295B2
(en)
|
2009-08-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
Cationic lipids with various head groups for oligonucleotide delivery
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
WO2011041639A2
(en)
|
2009-10-02 |
2011-04-07 |
Miller Raymond A |
Heteroatom containing substituted fatty acids
|
|
JP5723378B2
(ja)
*
|
2009-11-03 |
2015-05-27 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
トランスサイレチン（ｔｔｒ）を阻害する脂質製剤化組成物及び方法
|
|
SI2506857T1
(en)
|
2009-12-01 |
2018-08-31 |
Translate Bio, Inc. |
Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
|
|
US8846631B2
(en)
*
|
2010-01-14 |
2014-09-30 |
Regulus Therapeutics Inc. |
MicroRNA compositions and methods
|
|
US20130116419A1
(en)
|
2010-01-22 |
2013-05-09 |
Daniel Zewge |
Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
|
|
EP3391877A1
(en)
|
2010-04-08 |
2018-10-24 |
The Trustees of Princeton University |
Preparation of lipid nanoparticles
|
|
US20130129811A1
(en)
*
|
2010-04-28 |
2013-05-23 |
Takeshi Kuboyama |
Cationic lipid
|
|
KR101773643B1
(ko)
|
2010-04-28 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
양이온성 지질
|
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
|
US20130123338A1
(en)
*
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
WO2011141703A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
WO2011149733A2
(en)
|
2010-05-24 |
2011-12-01 |
Merck Sharp & Dohme Corp. |
Novel amino alcohol cationic lipids for oligonucleotide delivery
|
|
EP4481047A3
(en)
|
2010-06-03 |
2025-04-16 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
|
FI4005592T3
(fi)
|
2010-07-06 |
2023-01-13 |
|
Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
|
|
CN103153284B
(zh)
*
|
2010-07-06 |
2015-11-25 |
诺华股份有限公司 |
含有其pKa值有利于RNA递送的脂质的脂质体
|
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
|
WO2012016184A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US9193827B2
(en)
|
2010-08-26 |
2015-11-24 |
Massachusetts Institute Of Technology |
Poly(beta-amino alcohols), their preparation, and uses thereof
|
|
US20130253168A1
(en)
|
2010-08-31 |
2013-09-26 |
Steven L. Colletti |
Novel single chemical entities and methods for delivery of oligonucleotides
|
|
JP5911870B2
(ja)
|
2010-08-31 |
2016-04-27 |
ノバルティス アーゲー |
免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
|
|
WO2012031205A2
(en)
|
2010-09-03 |
2012-03-08 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
ES2987915T3
(es)
|
2010-09-20 |
2024-11-18 |
Sirna Therapeutics Inc |
Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
|
|
EP2621480B1
(en)
|
2010-09-30 |
2018-08-15 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR102266691B1
(ko)
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
WO2012054365A2
(en)
|
2010-10-21 |
2012-04-26 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
DK2635265T3
(en)
|
2010-11-05 |
2018-07-16 |
Sirna Therapeutics Inc |
New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
CA2831392C
(en)
|
2011-03-28 |
2020-04-28 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
EP4074693A1
(en)
|
2011-06-08 |
2022-10-19 |
Translate Bio, Inc. |
Cleavable lipids
|
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
|
RU2014104090A
(ru)
|
2011-07-06 |
2015-08-20 |
Новартис Аг |
Липосомы с эффективным соотношением n:p для доставки молекул phk
|
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
US9126966B2
(en)
*
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
US9271952B2
(en)
*
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
US9512073B2
(en)
|
2011-10-27 |
2016-12-06 |
Massachusetts Institute Of Technology |
Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
|
|
UA118649C2
(uk)
|
2011-11-18 |
2019-02-25 |
Елнілем Фармасьютікалз, Інк. |
ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
|
|
DE21212055T1
(de)
|
2011-12-07 |
2022-08-04 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
WO2013086322A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
WO2013110679A1
(en)
|
2012-01-27 |
2013-08-01 |
F. Hoffmann-La Roche Ag |
Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1
|
|
EP2806896B1
(en)
|
2012-01-27 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
|
|
BR112014013135A2
(pt)
|
2012-01-27 |
2017-12-05 |
Hoffmann La Roche |
composto, composição farmacêutica, método para o tratamento da inflamação, uso de um composto e invenção
|
|
US9586916B2
(en)
|
2012-01-27 |
2017-03-07 |
Hoffmann-La Roche Inc. |
Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3
|
|
US9352042B2
(en)
|
2012-02-24 |
2016-05-31 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
CN102600173B
(zh)
*
|
2012-03-02 |
2013-05-29 |
海南美兰史克制药有限公司 |
氨氯地平/贝那普利药物组合物脂质体固体制剂
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US10322089B2
(en)
*
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
WO2013143555A1
(en)
*
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
HK1206644A1
(en)
|
2012-03-29 |
2016-01-15 |
Shire Human Genetic Therapies, Inc. |
Lipid-derived neutral nanoparticles
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
CN104411338A
(zh)
*
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013158579A1
(en)
|
2012-04-19 |
2013-10-24 |
Merck Sharp & Dohme Corp. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
EA201492055A1
(ru)
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
|
TW201726599A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
WO2014028487A1
(en)
|
2012-08-13 |
2014-02-20 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
CA2891487A1
(en)
|
2012-11-29 |
2014-06-05 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
|
US20150366997A1
(en)
|
2012-12-07 |
2015-12-24 |
Shire Human Genetics Therapies, Inc. |
COMPOSITIONS AND METHODS FOR mRNA DELIVERY
|
|
EA201591229A1
(ru)
|
2013-03-14 |
2016-01-29 |
Шир Хьюман Дженетик Терапис, Инк. |
Способы очистки матричной рнк
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EP3932947A1
(en)
|
2013-03-14 |
2022-01-05 |
Translate Bio MA, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
KR102311614B1
(ko)
|
2013-03-14 |
2021-10-08 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
US8980864B2
(en)
*
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
ES2967701T3
(es)
|
2013-03-15 |
2024-05-03 |
Translate Bio Inc |
Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
US9315472B2
(en)
|
2013-05-01 |
2016-04-19 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
ES3032935T3
(en)
|
2013-10-22 |
2025-07-29 |
Translate Bio Inc |
Lipid formulations for delivery of messenger rna
|
|
ES2707966T3
(es)
|
2013-10-22 |
2019-04-08 |
Translate Bio Inc |
Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
|
|
AU2014340149B2
(en)
|
2013-10-22 |
2020-12-24 |
Shire Human Genetic Therapies, Inc. |
CNS delivery of mRNA and uses thereof
|
|
EP3574923A1
(en)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna therapy for phenylketonuria
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
WO2015126502A2
(en)
|
2013-12-03 |
2015-08-27 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
|
EP3093283B1
(en)
|
2014-01-09 |
2018-12-19 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
PL3122878T3
(pl)
|
2014-03-24 |
2019-06-28 |
Translate Bio, Inc. |
TERAPIA mRNA DO LECZENIA CHORÓB OCZU
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
EP4729528A3
(en)
|
2014-04-25 |
2026-06-24 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
MX384843B
(es)
|
2014-05-15 |
2025-03-14 |
Insmed Inc |
Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
|
|
CN105085295A
(zh)
*
|
2014-05-23 |
2015-11-25 |
上海交通大学 |
氨甲环酸的两亲性衍生物及其用途
|
|
CN105085292B
(zh)
*
|
2014-05-23 |
2017-12-15 |
上海交通大学 |
3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
|
|
WO2015184256A2
(en)
|
2014-05-30 |
2015-12-03 |
Shire Human Genetic Therapies, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
AU2015269412B2
(en)
|
2014-06-04 |
2020-03-12 |
Exicure Operating Company |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
KR102559979B1
(ko)
|
2014-06-24 |
2023-07-25 |
샤이어 휴먼 지네틱 테라피즈 인크. |
핵산의 전달용 입체화학적으로 풍부한 조성물
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
JP6641272B2
(ja)
|
2014-06-30 |
2020-02-05 |
協和キリン株式会社 |
カチオン性脂質
|
|
WO2016004318A1
(en)
|
2014-07-02 |
2016-01-07 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
|
WO2016004202A1
(en)
|
2014-07-02 |
2016-01-07 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
|
EP3183007B1
(en)
|
2014-08-19 |
2020-06-17 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
|
KR102410072B1
(ko)
|
2014-08-29 |
2022-06-20 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
|
AU2015357562B2
(en)
|
2014-12-05 |
2021-10-21 |
Translate Bio, Inc. |
Messenger RNA therapy for treatment of articular disease
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3270894B1
(en)
|
2015-03-19 |
2021-02-24 |
Translate Bio, Inc. |
Mrna therapy for pompe disease
|
|
WO2016153012A1
(ja)
*
|
2015-03-24 |
2016-09-29 |
協和発酵キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
US10780054B2
(en)
|
2015-04-17 |
2020-09-22 |
Curevac Real Estate Gmbh |
Lyophilization of RNA
|
|
WO2016176330A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
CN107683336A
(zh)
|
2015-05-06 |
2018-02-09 |
贝尼泰克生物制药有限公司 |
用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
|
|
CN104803863B
(zh)
*
|
2015-05-08 |
2016-07-20 |
厦门成坤生物技术有限公司 |
阳离子类脂化合物及其制备方法
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
CN107530448A
(zh)
|
2015-05-20 |
2018-01-02 |
库瑞瓦格股份公司 |
包含长链rna的干粉组合物
|
|
RS64331B1
(sr)
|
2015-06-19 |
2023-08-31 |
Massachusetts Inst Technology |
Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
CA2990521C
(en)
|
2015-07-07 |
2023-10-10 |
H. Lundbeck A/S |
Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
|
|
ES2898340T3
(es)
*
|
2015-07-09 |
2022-03-07 |
Insmed Inc |
Composiciones y métodos para tratar neumopatías y lesión pulmonar
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
LT3329002T
(lt)
|
2015-07-31 |
2021-01-11 |
Alnylam Pharmaceuticals, Inc. |
Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
MX2018002090A
(es)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
|
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
|
CN113440506A
(zh)
|
2015-10-02 |
2021-09-28 |
康普莱克夏公司 |
使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
ES2862412T3
(es)
|
2015-10-14 |
2021-10-07 |
Translate Bio Inc |
Modificación de enzimas relacionados con el ARN para producción mejorada
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
SG11201803360UA
(en)
|
2015-10-22 |
2018-05-30 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
|
MA45209A
(fr)
|
2015-10-22 |
2019-04-17 |
Modernatx Inc |
Vaccins contre les maladies sexuellement transmissibles
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
US12214054B2
(en)
|
2015-11-30 |
2025-02-04 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
|
CN106883158B
(zh)
*
|
2015-12-15 |
2019-08-23 |
中国科学院广州生物医药与健康研究院 |
生物可降解的氨基脂质类化合物及其制备方法和应用
|
|
RS63051B1
(sr)
|
2015-12-22 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularnu isporuku agenasa
|
|
US10525138B2
(en)
|
2015-12-25 |
2020-01-07 |
Kyowa Hakko Kirin Co., Ltd. |
Compound as cationic lipid
|
|
US12678515B2
(en)
|
2015-12-30 |
2026-07-14 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CN105622473B
(zh)
*
|
2016-02-06 |
2017-07-25 |
吴国球 |
一种阳离子氨基脂质及其合成方法和用途
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
AU2017248189B2
(en)
|
2016-04-08 |
2021-04-29 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
AU2017250017B2
(en)
|
2016-04-14 |
2022-12-22 |
Benitec IP Holdings Inc. |
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
|
|
CA3023451A1
(en)
|
2016-05-06 |
2017-11-09 |
Exicure, Inc. |
Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
|
|
CN114656378A
(zh)
*
|
2016-05-16 |
2022-06-24 |
得克萨斯州大学系统董事会 |
阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
|
|
PL3458074T3
(pl)
*
|
2016-05-16 |
2024-11-12 |
Board Of Regents Of The University Of Texas System |
KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
|
|
CN115837014A
(zh)
|
2016-05-18 |
2023-03-24 |
摩登纳特斯有限公司 |
编码松弛素的多核苷酸
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
AU2017283479B2
(en)
|
2016-06-13 |
2023-08-17 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
|
|
ES2948971T3
(es)
|
2016-06-24 |
2023-09-22 |
Eisai R&D Man Co Ltd |
Lípido catiónico
|
|
US11191849B2
(en)
*
|
2016-06-30 |
2021-12-07 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
CN109715205A
(zh)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
用于癌症治疗的rna
|
|
WO2018062233A1
(ja)
|
2016-09-27 |
2018-04-05 |
協和発酵キリン株式会社 |
カチオン性脂質としての化合物
|
|
WO2018062413A1
(ja)
*
|
2016-09-28 |
2018-04-05 |
協和発酵キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
US20190314486A1
(en)
|
2016-10-21 |
2019-10-17 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
JP7560946B2
(ja)
|
2016-11-10 |
2024-10-03 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの皮下送達
|
|
US20180153822A1
(en)
|
2016-11-10 |
2018-06-07 |
Translate Bio, Inc. |
Process of Preparing mRNA-Loaded Lipid Nanoparticles
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
WO2018104538A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
US11873496B2
(en)
|
2017-01-09 |
2024-01-16 |
Whitehead Institute For Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
|
EP3568155A4
(en)
|
2017-01-11 |
2020-09-23 |
The Trustees Of The University Of Pennsylvania |
RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
|
|
MA47515A
(fr)
|
2017-02-16 |
2019-12-25 |
Modernatx Inc |
Compositions immunogènes très puissantes
|
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
|
WO2018165257A1
(en)
|
2017-03-07 |
2018-09-13 |
Translate Bio, Inc. |
Polyanionic delivery of nucleic acids
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
MX2019011215A
(es)
|
2017-03-24 |
2020-02-12 |
Curevac Ag |
Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US11596679B2
(en)
|
2017-04-27 |
2023-03-07 |
Vanderbilt University |
Hepatitis C virus gene sequences and methods of use therefor
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
US11015204B2
(en)
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
|
EP3630200A4
(en)
|
2017-05-31 |
2021-02-24 |
Arcturus Therapeutics, Inc. |
THERAPEUTICS FOR PHENYLKETONURIA
|
|
KR102636537B1
(ko)
|
2017-05-31 |
2024-02-15 |
울트라제닉스 파마수티컬 인코포레이티드 |
글리코겐 축적 질환 유형 iii에 대한 치료제
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
US10780183B2
(en)
|
2017-06-19 |
2020-09-22 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of Friedreich's ataxia
|
|
JP7722629B2
(ja)
|
2017-07-04 |
2025-08-13 |
キュアバック エスイー |
新規核酸分子
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
CA3071968A1
(en)
|
2017-08-04 |
2019-02-07 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticle
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
WO2019048645A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
EP3684931A1
(en)
|
2017-09-19 |
2020-07-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
|
BR112020004351A2
(pt)
|
2017-10-19 |
2020-09-08 |
Curevac Ag |
moléculas de ácido nucleico artificial
|
|
SG11202003247RA
(en)
|
2017-11-08 |
2020-05-28 |
Curevac Ag |
Rna sequence adaptation
|
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
CN111542338B
(zh)
|
2017-12-27 |
2024-06-18 |
武田药品工业株式会社 |
含核酸脂质纳米粒子及其用途
|
|
WO2019131580A1
(ja)
|
2017-12-27 |
2019-07-04 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
WO2019147749A2
(en)
|
2018-01-29 |
2019-08-01 |
Merck Sharp & Dohme Corp. |
Stabilized rsv f proteins and uses thereof
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
US11975110B2
(en)
|
2018-02-02 |
2024-05-07 |
Translate Bio, Inc. |
Cationic polymers
|
|
WO2019155094A1
(en)
*
|
2018-02-12 |
2019-08-15 |
Interna Technologies B.V. |
Anticancer microrna and lipid formulations thereof
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
EP3773505B1
(en)
|
2018-03-30 |
2026-04-29 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
BR112020020479A2
(pt)
|
2018-04-09 |
2021-01-12 |
Checkmate Pharmaceuticals |
Empacotamento de oligonucleotídeos em partículas similares a vírus
|
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
EP3787602A4
(en)
|
2018-05-02 |
2022-03-23 |
Insmed Incorporated |
PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
|
|
EP3793689A1
(en)
|
2018-05-15 |
2021-03-24 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
AU2019271215B2
(en)
|
2018-05-16 |
2024-09-12 |
Translate Bio, Inc. |
Ribose cationic lipids
|
|
US12076439B2
(en)
|
2018-05-24 |
2024-09-03 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
BR112020024019A2
(pt)
|
2018-05-25 |
2021-02-23 |
Imara Inc. |
monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
|
|
AU2019277355A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
MA52762A
(fr)
|
2018-05-30 |
2021-04-14 |
Translate Bio Inc |
Lipides cationiques comprenant une fraction stéroïdienne
|
|
CN118436618A
(zh)
|
2018-05-30 |
2024-08-06 |
川斯勒佰尔公司 |
信使rna疫苗及其用途
|
|
EP3802507A1
(en)
|
2018-05-30 |
2021-04-14 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
WO2020023533A1
(en)
|
2018-07-23 |
2020-01-30 |
Translate Bio, Inc. |
Dry power formulations for messenger rna
|
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
EP3843709A1
(en)
|
2018-08-29 |
2021-07-07 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
KR20250108770A
(ko)
|
2018-08-31 |
2025-07-15 |
카듀리온 파마슈티칼스, 인크. |
겸상 세포 질환의 치료를 위한 pde9 억제제
|
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
ES2951836T3
(es)
|
2018-10-01 |
2023-10-25 |
Alnylam Pharmaceuticals Inc |
Lípidos biodegradables para el suministro de agentes activos
|
|
DK3864163T3
(da)
*
|
2018-10-09 |
2024-05-06 |
Univ British Columbia |
Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
|
|
CA3115751A1
(en)
|
2018-10-18 |
2020-04-23 |
Takeda Pharmaceutical Company Limited |
Method for activation/proliferation of t cells
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CN112888451A
(zh)
|
2018-10-19 |
2021-06-01 |
川斯勒佰尔公司 |
信使rna的无泵包封
|
|
US20220016265A1
(en)
|
2018-11-09 |
2022-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
AU2019376006B2
(en)
|
2018-11-09 |
2026-07-02 |
Arbutus Biopharma Corporation |
Cationic lipids containing silicon
|
|
WO2020097379A2
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
CA3117866A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
KR102860605B1
(ko)
|
2018-11-09 |
2025-09-15 |
트랜슬레이트 바이오 인코포레이티드 |
에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
|
|
EP3880174A2
(en)
|
2018-11-12 |
2021-09-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
US12257305B2
(en)
|
2018-11-21 |
2025-03-25 |
Translate Bio, Inc. |
Cationic lipid compounds
|
|
CA3122080A1
(en)
|
2018-12-06 |
2020-06-11 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
|
WO2020146344A1
(en)
|
2019-01-07 |
2020-07-16 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
PL3908568T3
(pl)
|
2019-01-11 |
2024-12-02 |
Acuitas Therapeutics, Inc. |
Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
EP3947646A1
(en)
|
2019-04-05 |
2022-02-09 |
Precision BioSciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
TWI887234B
(zh)
|
2019-04-14 |
2025-06-21 |
美國公爵大學 |
治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除
|
|
WO2020214946A1
(en)
|
2019-04-18 |
2020-10-22 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
EP3959195B1
(en)
|
2019-04-22 |
2023-11-08 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
WO2020227085A1
(en)
|
2019-05-03 |
2020-11-12 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
AU2020274758B2
(en)
|
2019-05-14 |
2025-05-01 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
|
JP7686574B2
(ja)
|
2019-05-22 |
2025-06-02 |
マサチューセッツ インスティテュート オブ テクノロジー |
環状ｒｎａ組成物及び方法
|
|
EP3976593A1
(en)
|
2019-05-31 |
2022-04-06 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
EP3986858A1
(en)
|
2019-06-21 |
2022-04-27 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
|
CA3145425A1
(en)
*
|
2019-07-03 |
2021-01-07 |
Factor Bioscience Inc. |
Cationic lipids and uses thereof
|
|
CA3146369A1
(en)
|
2019-07-08 |
2021-01-14 |
Translate Bio, Inc. |
Improved mrna-loaded lipid nanoparticles and processes of making the same
|
|
CA3147875A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
JP7630904B2
(ja)
*
|
2019-07-23 |
2025-02-18 |
株式会社東芝 |
核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
|
|
AU2020315962B2
(en)
|
2019-07-23 |
2026-02-12 |
Translate Bio, Inc. |
Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
|
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
|
IL290078B2
(en)
|
2019-07-30 |
2025-09-01 |
Translate Bio Inc |
Treatment of cystic fibrosis by administering mRNA encoding CFTR in the form of a fine spray
|
|
WO2021028439A1
(en)
|
2019-08-14 |
2021-02-18 |
Curevac Ag |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
AU2020351220A1
(en)
|
2019-09-19 |
2022-04-07 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4031524A1
(en)
|
2019-09-19 |
2022-07-27 |
ModernaTX, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Sepia Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
EP4529928A3
(en)
|
2019-10-09 |
2025-05-28 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
CA3155074A1
(en)
*
|
2019-10-18 |
2021-04-22 |
The Trustees Of The University Of Pennsylvania |
Lipid and lipid nanoparticle formulation for drug delivery
|
|
EP4048316A1
(en)
|
2019-10-21 |
2022-08-31 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
MX2022006854A
(es)
|
2019-12-04 |
2022-11-30 |
Orna Therapeutics Inc |
Composiciones y metodos de arn circular.
|
|
MX2022007756A
(es)
|
2019-12-20 |
2022-09-27 |
Translate Bio Inc |
Suministro rectal de arn mensajero.
|
|
JP2023508881A
(ja)
|
2019-12-20 |
2023-03-06 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
|
|
CA3162019A1
(en)
|
2019-12-20 |
2021-06-24 |
Gemma NAVARRO |
Lipid nanoparticles for delivery of nucleic acids
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
DE202021004130U1
(de)
|
2020-02-04 |
2022-10-26 |
Curevac Ag |
Coronavirus-Vakzine
|
|
US12673103B2
(en)
|
2020-02-14 |
2026-07-07 |
Merck Sharp & Dohme Llc |
HPV vaccine
|
|
CN115427021A
(zh)
|
2020-02-25 |
2022-12-02 |
翻译生物公司 |
制备负载mrna的脂质纳米颗粒的改进方法
|
|
EP4114470A4
(en)
|
2020-03-03 |
2024-04-17 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY
|
|
JP2023517644A
(ja)
|
2020-03-09 |
2023-04-26 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
コロナウイルスワクチン組成物及び方法
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral DNA vectors and their use for therapeutic expression of factor ix
|
|
CA3178344A1
(en)
|
2020-03-31 |
2021-10-07 |
The Trustees Of The University Of Pennsylvania |
Universal influenza vaccine using nucleoside-modified mrna
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
AU2021252164B2
(en)
|
2020-04-09 |
2026-07-02 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
WO2021222801A2
(en)
|
2020-05-01 |
2021-11-04 |
Arcturus Therapeutics, Inc. |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
AU2021269042A1
(en)
|
2020-05-07 |
2023-02-02 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding SARS-CoV-2 antigens
|
|
WO2021226463A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
WO2021226468A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
ES3066134T3
(en)
|
2020-05-14 |
2026-05-11 |
Translate Bio Inc |
Peg lipidoid compounds
|
|
JP7873638B2
(ja)
|
2020-05-15 |
2026-06-12 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡ送達のための脂質ナノ粒子製剤
|
|
CN116322788A
(zh)
|
2020-05-19 |
2023-06-23 |
奥纳治疗公司 |
环状rna组合物和方法
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
AU2021275223A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc. |
Coronavirus antigen compositions and their uses
|
|
US20230203510A1
(en)
|
2020-05-29 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
WO2021239880A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
EP4178544A4
(en)
|
2020-07-08 |
2024-09-25 |
The Trustees of the University of Pennsylvania |
NUCLEOSIDE-MODIFIED RNA TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS
|
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
|
MX2023001109A
(es)
|
2020-07-27 |
2023-04-24 |
Anjarium Biosciences Ag |
Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
TW202220637A
(zh)
*
|
2020-08-06 |
2022-06-01 |
美商現代公司 |
製備脂質奈米顆粒之方法
|
|
US12178921B2
(en)
|
2020-08-14 |
2024-12-31 |
Arcturus Therapeutics, Inc. |
Method of lyophilizing lipid nanoparticles
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2022043551A2
(en)
|
2020-08-31 |
2022-03-03 |
Curevac Ag |
Multivalent nucleic acid based coronavirus vaccines
|
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
IL301253A
(en)
|
2020-09-13 |
2023-05-01 |
Arcturus Therapeutics Inc |
As a mass of large RNA lipid nanoparticles
|
|
CA3194863A1
(en)
|
2020-10-06 |
2022-04-14 |
Shrirang KARVE |
Improved process and formulation of lipid nanoparticles
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
CA3198411A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
US12678406B2
(en)
|
2020-10-12 |
2026-07-14 |
Translate Bio Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
MX2023004371A
(es)
|
2020-10-14 |
2023-07-26 |
George Mason Res Foundation Inc |
Lípidos ionizables, y métodos de fabricación y uso de los mismos.
|
|
US12576030B2
(en)
|
2020-11-09 |
2026-03-17 |
Translate Bio, Inc. |
Compositions for delivery of codon-optimized mRNA
|
|
JP7872268B2
(ja)
|
2020-11-25 |
2026-06-09 |
トランスレイト バイオ， インコーポレイテッド |
安定な液状脂質ナノ粒子製剤
|
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
KR20230135585A
(ko)
|
2020-12-23 |
2023-09-25 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변형된 trem의 조성물 및 이의 용도
|
|
AU2021412833A1
(en)
|
2020-12-28 |
2023-07-06 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
US20250268994A1
(en)
|
2021-03-25 |
2025-08-28 |
Translate Bio, Inc. |
Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
|
|
US20240175033A1
(en)
|
2021-03-26 |
2024-05-30 |
Mina Therapeutics Limited |
TMEM173 saRNA Compositions and Methods of Use
|
|
EP4313152A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
|
EP4312988A2
(en)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4323770A1
(en)
*
|
2021-04-12 |
2024-02-21 |
Institut Curie |
Folr2+ macrophages and anti-tumor immunity
|
|
CA3215606A1
(en)
|
2021-04-19 |
2022-10-27 |
Shrirang KARVE |
Improved compositions for delivery of mrna
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
|
|
JP2024515788A
(ja)
|
2021-04-27 |
2024-04-10 |
ジェネレーション バイオ カンパニー |
治療抗体を発現する非ウイルスｄｎａベクター及びその使用
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
US20240300914A1
(en)
*
|
2021-05-28 |
2024-09-12 |
Nanovation Therapeutics Inc. |
KC2-Type Lipids
|
|
CN117460542A
(zh)
|
2021-06-11 |
2024-01-26 |
纳米智能生物医学工程有限公司 |
包含用于将寡核苷酸递送至靶细胞内的肽-脂质缀合物的纳米颗粒以及包含其的药物组合物
|
|
EP4362920A1
(en)
|
2021-07-01 |
2024-05-08 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4377331A2
(en)
|
2021-07-30 |
2024-06-05 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
AR126675A1
(es)
|
2021-08-03 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO
|
|
AR126813A1
(es)
|
2021-08-19 |
2023-11-15 |
Merck Sharp & Dohme Llc |
Nueva nanopartícula lipídica termostable y métodos de uso de la misma
|
|
CN113461577B
(zh)
*
|
2021-09-01 |
2021-12-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其应用
|
|
IL309502A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
|
|
CN115745941B
(zh)
*
|
2021-09-03 |
2025-07-01 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
EP4763287A2
(en)
|
2021-09-03 |
2026-06-24 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CN115745942B
(zh)
*
|
2021-09-03 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115772089B
(zh)
*
|
2021-09-07 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
EP4419706A1
(en)
|
2021-10-18 |
2024-08-28 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
JP2024545572A
(ja)
|
2021-11-10 |
2024-12-10 |
トランスレイト バイオ， インコーポレイテッド |
原発性線毛機能不全の治療のための組成物及び方法
|
|
JP2024546431A
(ja)
|
2021-11-11 |
2024-12-24 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
Ｒｎａ送達のためのイオン化可能なカチオン性脂質
|
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
MX2024006407A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de inmunogenos del virus varicela-zoster y sus usos.
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CN118510896A
(zh)
|
2021-12-17 |
2024-08-16 |
旗舰创业创新六公司 |
用于在变性条件下富集环状rna的方法
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
AU2022420620A1
(en)
|
2021-12-23 |
2024-07-04 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
EP4493212A1
(en)
|
2022-03-14 |
2025-01-22 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
CA3245624A1
(en)
|
2022-03-25 |
2023-09-28 |
Sail Biomedicines, Inc. |
NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE
|
|
CA3247022A1
(en)
*
|
2022-03-28 |
2025-07-08 |
National University Corporation Chiba University |
METHOD FOR PRODUCING LIPID NANOPARTICLES ENCAPSULATED IN A NUCLEIC ACID, METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION CONTAINING SAID LIPID NANOPARTICLES, AND METHOD FOR INTRODUCING NUCLEIC ACID INTO A CELL OR A TARGET CELL
|
|
US12011507B2
(en)
|
2022-04-01 |
2024-06-18 |
Nanovation Therapeutics Inc. |
MRNA delivery composition
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
WO2023214405A1
(en)
|
2022-05-01 |
2023-11-09 |
Yeda Research And Development Co. Ltd. |
Reexpression of hnf4a to alleviate cancer-associated cachexia
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
JP2025516638A
(ja)
|
2022-05-13 |
2025-05-30 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
二本鎖ｄｎａ組成物及び関連する方法
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023230587A2
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
CA3248209A1
(en)
|
2022-05-25 |
2023-11-30 |
CureVac SE |
Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
|
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
CA3260237A1
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
|
|
US20250375524A1
(en)
|
2022-06-30 |
2025-12-11 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
|
EP4554967A2
(en)
|
2022-07-12 |
2025-05-21 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
EP4581012A2
(en)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CN120152962A
(zh)
|
2022-09-06 |
2025-06-13 |
国立大学法人九州大学 |
脂质纳米粒子
|
|
JP2025531268A
(ja)
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
Ｔ細胞機能を調節するための組成物、システム、および方法
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
US20240108545A1
(en)
|
2022-10-03 |
2024-04-04 |
West Pharmaceutical Services, Inc. |
Methods and adapters for mixing pharmaceutical complexes
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024086929A1
(en)
*
|
2022-10-25 |
2024-05-02 |
Nanovation Therapeutics Inc. |
Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
TW202428289A
(zh)
|
2022-11-08 |
2024-07-16 |
美商歐納醫療公司 |
環狀rna組合物
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102799A1
(en)
|
2022-11-08 |
2024-05-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
|
EP4622630A1
(en)
|
2022-11-21 |
2025-10-01 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
US20260207525A1
(en)
|
2022-12-01 |
2026-07-23 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
JP2025541845A
(ja)
|
2022-12-09 |
2025-12-23 |
ソウル大学校産学協力団 |
Ｂ細胞及びＴ細胞内へｍＲＮＡを伝達するためのペプチド基盤結合体を含むナノ粒子及びこの用途
|
|
WO2024123139A1
(ko)
|
2022-12-09 |
2024-06-13 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
WO2024121814A1
(en)
|
2022-12-09 |
2024-06-13 |
Takeda Pharmaceutical Company Limited |
Modified immunomodulators
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
TW202440929A
(zh)
|
2022-12-14 |
2024-10-16 |
加拿大商普羅維登斯治療控股公司 |
用於感染性疾病的組合物和方法
|
|
EP4634390A2
(en)
|
2022-12-15 |
2025-10-22 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
TW202438514A
(zh)
|
2022-12-20 |
2024-10-01 |
法商賽諾菲公司 |
鼻病毒mrna疫苗
|
|
US20260218178A1
(en)
|
2022-12-22 |
2026-07-30 |
Mina Therapeutics Limited |
Chemically Modified saRNA Compositions and Methods of Use
|
|
EP4642481A2
(en)
|
2022-12-29 |
2025-11-05 |
Popvax Private Limited |
Multitarget vaccines and therapeutics
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
US12410394B2
(en)
*
|
2023-01-06 |
2025-09-09 |
Athergen, Inc. |
Composition comprising nicotinamide mononucleotide and leucomethylene blue
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
IL322368A
(en)
|
2023-02-03 |
2025-09-01 |
Genzyme Corp |
HSC-specific antibody-conjugated lipid nanoparticles and their uses
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
EP4662196A1
(en)
*
|
2023-02-09 |
2025-12-17 |
Seqirus Inc. |
Ionizable cationic compound
|
|
US20240293318A1
(en)
|
2023-02-13 |
2024-09-05 |
Flagship Pioneering Innovations Vii, Llc |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
TW202446956A
(zh)
|
2023-02-17 |
2024-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
包含經修飾的胞嘧啶的ｄｎａ組成物
|
|
KR20250151437A
(ko)
|
2023-02-17 |
2025-10-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
변형된 우라실을 포함하는 dna 조성물
|
|
KR20250153298A
(ko)
|
2023-03-08 |
2025-10-24 |
큐어백 에스이 |
핵산 전달을 위한 신규의 지질 나노입자 제형
|
|
EP4680276A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
EP4680750A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
JP2026512425A
(ja)
|
2023-03-30 |
2026-04-16 |
オーエスイー・イミュノセラピューティクス |
免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
|
|
TW202449142A
(zh)
|
2023-04-07 |
2024-12-16 |
日商武田藥品工業股份有限公司 |
接合複合物
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
MX2025012337A
(es)
|
2023-04-17 |
2026-02-03 |
Sanofi Pasteur Inc |
Formulaciones de polvo seco reconstituibles y métodos de uso de las mismas
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
JP2026518411A
(ja)
|
2023-04-27 |
2026-06-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスワクチン
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
TW202509222A
(zh)
|
2023-05-08 |
2025-03-01 |
美商默沙東有限責任公司 |
編碼諾羅病毒vp1抗原之多核苷酸及其用途
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
|
JP2026518633A
(ja)
|
2023-05-15 |
2026-06-09 |
武田薬品工業株式会社 |
細胞への核酸の送達のための組成物及び方法
|
|
CN116270543B
(zh)
*
|
2023-05-19 |
2023-09-26 |
清华大学 |
脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
|
|
EP4716741A2
(en)
|
2023-05-23 |
2026-04-01 |
Flagship Labs 114, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
EP4719352A1
(en)
|
2023-05-31 |
2026-04-08 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
CR20250529A
(es)
|
2023-06-09 |
2026-01-12 |
Merck Sharp & Dohme Llc |
Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
TW202515531A
(zh)
|
2023-07-07 |
2025-04-16 |
美商輝瑞股份有限公司 |
兩親性ｔｌｒ７／８佐劑及其用途
|
|
KR20260044217A
(ko)
|
2023-07-25 |
2026-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
Cas 엔도뉴클레아제 및 관련 방법
|
|
EP4758176A1
(en)
*
|
2023-07-31 |
2026-06-17 |
Jibe Therapeutics, Inc. |
Compositions for redirecting immunoglobulins to immune cells
|
|
CN121909284A
(zh)
|
2023-07-31 |
2026-04-21 |
图恩疗法股份有限公司 |
用于调节il-2基因表达的组合物和方法
|
|
EP4754248A1
(en)
|
2023-07-31 |
2026-06-10 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
EP4771042A1
(en)
|
2023-08-29 |
2026-07-08 |
Shanghai Circode Biomed Co., Ltd |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
IL327035A
(en)
|
2023-09-18 |
2026-05-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipidoid compositions and their medical uses
|
|
CN121909024A
(zh)
*
|
2023-09-22 |
2026-04-21 |
国立大学法人东北大学 |
包封有核酸的配体修饰脂质纳米颗粒的制造方法
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
CN122497525A
(zh)
|
2023-11-07 |
2026-07-31 |
欧纳医疗公司 |
环状rna组合物
|
|
KR20260113064A
(ko)
|
2023-11-14 |
2026-07-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
이온화 가능한 리피도이드 조성물 및 이의 치료적 용도
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025133115A1
(en)
|
2023-12-21 |
2025-06-26 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising il-35
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
TW202543581A
(zh)
|
2024-02-12 |
2025-11-16 |
美商艾伊拉醫療公司 |
遞送組成物
|
|
WO2025180874A1
(en)
*
|
2024-02-27 |
2025-09-04 |
Basf Se |
Substituted 1,3-dioxolane sulfates and their use
|
|
TW202600536A
(zh)
*
|
2024-03-07 |
2026-01-01 |
日商日東電工股份有限公司 |
脂質奈米粒子
|
|
WO2025190300A1
(zh)
*
|
2024-03-13 |
2025-09-18 |
仁景(苏州)生物科技有限公司 |
脂质纳米颗粒及脂质纳米颗粒组合物
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
CN118388360B
(zh)
|
2024-04-17 |
2025-04-04 |
北京悦康科创医药科技股份有限公司 |
含有苯环结构的长效脾靶向阳离子脂质化合物、包含其的组合物及用途
|
|
TW202613158A
(zh)
|
2024-05-16 |
2026-04-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250751A1
(en)
|
2024-05-31 |
2025-12-04 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2025252759A1
(en)
|
2024-06-03 |
2025-12-11 |
Bio-Sourcing |
Transient expression by lipid nanoparticle formulations
|
|
WO2025259931A1
(en)
|
2024-06-14 |
2025-12-18 |
Orbital Therapeutics, Inc. |
Compositions and methods for rna circularization
|
|
WO2026006203A2
(en)
|
2024-06-24 |
2026-01-02 |
Orbital Therapeutics, Inc. |
Compositions and methods for making circular rna
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026033123A1
(en)
|
2024-08-08 |
2026-02-12 |
Sanofi Pasteur Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|
|
WO2026072557A2
(en)
|
2024-09-24 |
2026-04-02 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
WO2026088119A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026088120A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026093414A1
(en)
|
2024-10-30 |
2026-05-07 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising membrane il-35
|
|
WO2026093616A1
(en)
|
2024-11-04 |
2026-05-07 |
Variant |
Nucleic acid encoding cone-rod homeobox (crx) protein, and expression vectors thereof, for use in treating a ciliopathy
|
|
WO2026102108A1
(en)
|
2024-11-07 |
2026-05-15 |
Flagship Pioneering Innovations Vii, Llc |
Dna production methods
|
|
WO2026112559A1
(en)
|
2024-11-25 |
2026-05-28 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2026117631A2
(en)
|
2024-11-26 |
2026-06-04 |
City Therapeutics, Inc. |
Factor xi rnai agent compositions and methods of use thereof
|
|
WO2026117519A1
(en)
|
2024-11-27 |
2026-06-04 |
Merck Sharp & Dohme Llc |
Nanoemulsion adjuvant compositions for epstein barr virus vaccines
|
|
WO2026122747A2
(en)
|
2024-12-05 |
2026-06-11 |
Flagship Pioneering Innovations Vii, Llc |
Novel immunomodulatory proteins and related methods
|
|
WO2026134350A1
(en)
|
2024-12-20 |
2026-06-25 |
Takeda Pharmaceutical Company Limited |
Lipid nano-particle having a ligand targeted to cd7 and chimeric antigen receptor and use thereof
|
|
WO2026152023A1
(en)
|
2025-01-10 |
2026-07-16 |
Sail Biomedicines, Inc. |
Lipid compounds, lipid nanoparticle compositions and use thereof with polyribonucleotides
|
|
WO2026151879A1
(en)
|
2025-01-10 |
2026-07-16 |
Flagship Pioneering Innovations Vii, Llc |
Vaccine compositions and methods
|
|
WO2026152164A1
(en)
|
2025-01-13 |
2026-07-16 |
Sail Biomedicines, Inc. |
Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo
|
|
WO2026161895A1
(en)
|
2025-01-27 |
2026-07-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression
|